Optimizing the Identification of HER2-Low Breast Cancer
Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayTestingHER2LowBC24).
